Verus Capital Partners LLC Invests $441,000 in Kenvue Inc. $KVUE

Verus Capital Partners LLC bought a new stake in Kenvue Inc. (NYSE:KVUE) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 27,150 shares of the company’s stock, valued at approximately $441,000.

Several other hedge funds also recently modified their holdings of KVUE. Norges Bank acquired a new stake in Kenvue during the second quarter worth approximately $537,418,000. Independent Franchise Partners LLP lifted its stake in shares of Kenvue by 233.4% during the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares in the last quarter. American Century Companies Inc. boosted its holdings in Kenvue by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock worth $633,447,000 after acquiring an additional 8,436,166 shares during the period. Amundi boosted its stake in shares of Kenvue by 82.5% in the second quarter. Amundi now owns 14,509,890 shares of the company’s stock valued at $305,446,000 after purchasing an additional 6,559,261 shares during the period. Finally, Mondrian Investment Partners LTD acquired a new stake in shares of Kenvue during the third quarter valued at about $79,269,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KVUE. UBS Group raised their price target on shares of Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 18th. Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Barclays lifted their price target on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Finally, Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.50.

Insider Buying and Selling at Kenvue

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of Kenvue stock in a transaction that occurred on Friday, December 12th. The stock was acquired at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Kenvue Price Performance

Shares of NYSE KVUE opened at $19.02 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.69. The firm has a market capitalization of $36.46 billion, a PE ratio of 24.71, a P/E/G ratio of 4.34 and a beta of 0.59. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The business’s fifty day moving average price is $17.61 and its two-hundred day moving average price is $17.55.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.05. The company had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. On average, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be paid a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.4%. Kenvue’s payout ratio is presently 107.79%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.